All In Biotech

Drug Trial Radar · NCT03208985

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions

A Multi-Center, Open-Label Trial Investigating Behavior Related to Ella® Use in a Simulated OTC Environment (LIBRella)

Last checked: Nov 20, 2026Latest source record: Dec 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,270

Actual

Start

May 23, 2017

Primary completion

Jun 14, 2018

Study completion Jun 14, 2018

Sponsor

Lead sponsor
HRA PharmaIndustry
Sponsor type
Industry
First posted
Jul 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to assess whether consumers select and use ella® (ulipristal acetate 30mg), an emergency contraceptive, in a manner consistent with the OTC package directions in an OTC-like setting.

Conditions

  • Emergency Contraception

Interventions

  • Use Phase (Ulipristal Acetate, 30 mg)Drug

    All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate. Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Dosing Instances Among User Population Taken Within 120 Hours (5 Days) of Most Recent Episode of Unprotected Sex.Time frame: Up to 6 Weeks
  2. Proportion of Dosing Instances Among User Population in Which no More Than One Tablet Was Taken.Time frame: Up to 6 Weeks
  3. Proportion of Female Selectors Who Are Not Pregnant at the Time of Selection Decision.Time frame: Day 1

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • HRA Pharma Investigational Site

    Rancho Cucamonga, California

  • HRA Pharma Investigational Site

    Boulder, Colorado

  • HRA Pharma Investigational Site

    Denver, Colorado

  • HRA Pharma Investigational Site

    Denver, Colorado

  • HRA Pharma Investigational Site

    Fort Myers, Florida

  • HRA Pharma Investigational Site

    Miami, Florida

  • HRA Pharma Investigational Site

    Orlando, Florida

  • HRA Pharma Investigational Site

    Pembroke Pines, Florida

  • HRA Pharma Investigational Site

    St. Petersburg, Florida

  • HRA Pharma Investigational Site

    Tampa, Florida

  • HRA Pharma Investigational Site

    Belleville, Illinois

  • HRA Pharma Investigational Site

    Andover, Minnesota

  • HRA Pharma Investigational Site

    Saint Louis Park, Minnesota

  • HRA Pharma Investigational Site

    City of Saint Peters, Missouri

  • HRA Pharma Investigational Site

    Kansas City, Missouri

  • HRA Pharma Investigational Site

    Manchester, Missouri

  • HRA Pharma Investigational Site

    St Louis, Missouri

  • HRA Pharma Investigational Site

    St Louis, Missouri

  • HRA Pharma Investigational Site

    Las Vegas, Nevada

  • HRA Pharma Investigational Site

    Hackensack, New Jersey

  • HRA Pharma Investigational Site

    Morristown, New Jersey

  • HRA Pharma Investigational Site

    New Brunswick, New Jersey

  • HRA Pharma Investigational Site

    Trenton, New Jersey

  • HRA Pharma Investigational Site

    Albuquerque, New Mexico

  • HRA Pharma Investigational Site

    Albuquerque, New Mexico

  • HRA Pharma Investigational Site

    New York, New York

  • HRA Pharma Investigational Site

    Durham, North Carolina

  • HRA Pharma Investigational Site

    Raleigh, North Carolina

  • HRA Pharma Investigational Site

    Portland, Oregon

  • HRA Pharma Investigational Site

    Bremerton, Washington

  • HRA Pharma Investigational Site

    Puyallup, Washington

  • HRA Pharma Investigational Site

    Seattle, Washington

  • HRA Pharma Investigational Site

    Seattle, Washington

  • HRA Pharma Investigational Site

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.